Mediclarum
Medicine guide

Mesna

100 mg/mL · Injection, Solution

  • Prescription only
  • Cytoprotective Agent
Active substance
Mesna
Made by
Eugia US LLC

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2026-01-27

What it is

Cytoprotective Agent

Used for
The label’s usual adult dose

0 Hours 4 Hours 8 Hours Ifosfamide 1.2 g/m 2 -- -- Mesna injection 240 mg/m 2 240 mg/m 2 240 mg/m 2 Intravenous and Oral Dosing Schedule:

Full directions ↓
Do not take it if

CONTRAINDICATIONS Mesna injection is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see Warnings and Precautions (5.1) ] .

All warnings ↓
Good to know
  • Prescription only
  • FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
8other products contain Mesna — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

Limitation of Use:

  • 1.
  • INDICATIONS AND USAGE Mesna injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
  • Mesna injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia.
  • Mesna injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
  • ( 1 ) Limitation of Use:
  • Mesna injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia.
  • ( 1 )

From the official label · 2026-01-27 · DailyMed

How it works

From this product’s own US prescribing label.

Mesna reacts chemically with the urotoxic ifosfamide metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification.

The first step in the detoxification process is the binding of mesna to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide.

Peak level after1.5–4 h
How it leaves the body

Following intravenous administration of a single 800 mg dose, approximately 32% and 33% of the administered dose was eliminated in the urine in 24 hours as mesna and dimesna, respectively.

With food

Food does not affect the urinary availability of orally administered mesna.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-27

Do not take it if

  • 4.
  • CONTRAINDICATIONS Mesna injection is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see Warnings and Precautions (5.1) ] .
  • Known hypersensitivity to mesna or to any of the excipients in mesna injection, including benzyl alcohol.
  • ( 4 )

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

  • 2.
  • DOSAGE AND ADMINISTRATION Mesna injection may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below.
  • The dosing schedule should be repeated on each day that ifosfamide is administered.
  • When the dosage of ifosfamide is adjusted, the ratio of mesna to ifosfamide should be maintained.
  • ( 2 ) Intravenous Dosing Schedule:
  • 0 Hours 4 Hours 8 Hours Ifosfamide 1.2 g/m 2 -- -- Mesna injection 240 mg/m 2 240 mg/m 2 240 mg/m 2 Intravenous and Oral Dosing Schedule:
  • 0 Hours 2 Hours 6 Hours Ifosfamide 1.2 g/m 2 -- -- Mesna injection 240 mg/m 2 -- -- MESNEX tablets -- 480 mg/m 2 480 mg/m 2 Maintain sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria.
  • ( 2.3 )
  • 2.1 Intravenous Dosing Mesna injection may be given on a fractionated dosing schedule of three bolus intravenous injections as outlined below.
  • Mesna injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage weight by weight (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide.
  • The total daily dose of mesna injection is 60% of the ifosfamide dose.
  • The recommended dosing schedule is outlined below in Table 1 .
  • Table 1.
  • Recommended Intravenous Dosing Schedule 1 The dosing schedule should be repeated on each day that ifosfamide is administered.
  • When the dosage of ifosfamide is increased or decreased, the ratio of mesna to ifosfamide should be maintained. 0 Hours 4 Hours 8 Hours Ifosfamide 1.2 g/m 2 - - Mesna injection 1 240 mg/m 2 240 mg/m 2 240 mg/m 2
  • 2.2 Intravenous and Oral Dosing Mesna injection may be given on a fractionated dosing schedule of a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below.
  • Mesna injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration.
  • MESNEX tablets are given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide.
  • The total daily dose of mesna is 100% of the ifosfamide dose.
  • The recommended dosing schedule is outlined in Table 2 .
  • Table 2.
  • Recommended Intravenous and Oral Dosing Schedule 1 The dosing schedule should be repeated on each day that ifosfamide is administered.
  • When the dosage of ifosfamide is increased or decreased, the ratio of mesna to ifosfamide should be maintained. 0 Hours 2 Hours 6 Hours Ifosfamide 1.2 g/m 2 - - Mesna injection 1 240 mg/m 2 - - MESNEX tablets - 480 mg/m 2 480 mg/m 2 The efficacy and safety of this ratio of intravenous and oral MESNEX has not been established as being effective for daily doses of ifosfamide higher than 2 g/m 2 .
  • Patients who vomit within two hours of taking oral MESNEX should repeat the dose or receive intravenous mesna injection.
  • 2.3 Monitoring for Hematuria Maintain adequate hydration and sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria.
  • If severe hematuria develops when mesna injection is given according to the recommended dosage schedule, dosage reductions or discontinuation of ifosfamide therapy may be required.
  • 2.4 Preparation for Intravenous Administration and Stability Preparation Determine the volume of mesna injection for the intended dose.
  • Dilute the volume of mesna injection for the dose in any of the following fluids to obtain a final concentration of 20 mg/mL:
  • 5% Dextrose Injection, USP 5% Dextrose and 0.2% Sodium Chloride Injection, USP 5% Dextrose and 0.33% Sodium Chloride Injection, USP 5% Dextrose and 0.45% Sodium Chloride Injection, USP 0.9% Sodium Chloride Injection, USP Lactated Ringer’s Injection, USP Stability The mesna injection multidose vials may be stored and used for up to 8 days after initial puncture.
  • Store diluted solutions at 25°C (77°F).
  • Use diluted solutions within 24 hours.
  • Do not mix mesna injection with epirubicin, cyclophosphamide, cisplatin, carboplatin, and nitrogen mustard.
  • The benzyl alcohol contained in mesna injection vials can reduce the stability of ifosfamide.
  • Ifosfamide and mesna injection may be mixed in the same bag provided the final concentration of ifosfamide does not exceed 50 mg/mL.
  • Higher concentrations of ifosfamide may not be compatible with mesna injection and may reduce the stability of ifosfamide.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
  • Any solutions which are discolored, hazy, or contain visible particulate matter should not be used.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

  • 5.
  • WARNINGS AND PRECAUTIONS Hypersensitivity reactions:
  • Anaphylactic reactions have been reported.
  • Less severe hypersensitivity reactions may also occur.
  • Monitor patients.
  • If a reaction occurs, discontinue mesna injection and provide supportive care.
  • ( 5.1 ) Dermatologic toxicity:
  • Skin rash with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis have occurred.
  • Skin rash, urticaria, and angioedema have also been seen.
  • Monitor patients.
  • If a reaction occurs, discontinue mesna injection and provide supportive care.
  • ( 5.2 ) Benzyl alcohol toxicity:
  • Serious and fatal adverse reactions can occur in premature neonates and low-birth weight infants treated with benzyl alcohol-preserved drugs, including mesna injection.
  • Avoid use in premature neonates and low-birth weight infants.
  • ( 5.3 ) Laboratory test alterations:
  • False positive tests for urinary ketones and interference with enzymatic CPK activity tests have been seen.
  • ( 5.4 )
  • 5.1 Hypersensitivity Reactions Mesna injection may cause systemic hypersensitivity reactions, including anaphylaxis.
  • These reactions may include fever, cardiovascular symptoms (hypotension, tachycardia), acute renal impairment, hypoxia, respiratory distress, urticaria, angioedema, laboratory signs of disseminated intravascular coagulation, hematological abnormalities, increased liver enzymes, nausea, vomiting, arthralgia, and myalgia.
  • These reactions may occur with the first exposure or after several months of exposure.
  • Monitor for signs or symptoms.
  • Discontinue mesna injection and provide supportive care.
  • 5.2 Dermatologic Toxicity Drug rash with eosinophilia and systemic symptoms and bullous and ulcerative skin and mucosal reactions, consistent with Stevens-Johnson syndrome or toxic epidermal necrolysis have occurred.
  • Mesna injection may cause skin and mucosal reactions characterized by urticaria, rash, erythema, pruritus, burning sensation, angioedema, periorbital edema, flushing and stomatitis.
  • These reactions may occur with the first exposure or after several months of exposure.
  • Discontinue mesna injection and provide supportive care.
  • 5.3 Benzyl Alcohol Toxicity Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and low-birth weight infants who received benzyl alcohol dosages of 99 to 234 mg/kg/day (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L).
  • Symptoms associated with “gasping syndrome” and other potential adverse reactions include gradual neurological deterioration, seizures, intracranial hemorrhage, hematological abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse.
  • Premature neonates and low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol.
  • The minimum amount of benzyl alcohol at which toxicity may occur is not known.
  • Mesna injection contains 10.4 mg/mL of the preservative benzyl alcohol.
  • MESNEX tablets do not contain benzyl alcohol [see Use in Specific Populations (8.4) ] .
  • 5.4 Laboratory Test Interferences False-Positive Urine Tests for Ketone Bodies A false positive test for urinary ketones may arise in patients treated with mesna
  • when using nitroprusside sodium-based urine tests (including dipstick tests).
  • The addition of glacial acetic acid can be used to differentiate between a false positive result (cherry-red color that fades) and a true positive result (red-violet color that intensifies).
  • False-Negative Tests for Enzymatic CPK Activity Mesna may interfere with enzymatic creatinine phosphokinase (CPK) activity tests that use a thiol compound (e.g., N-acetylcysteine) for CPK reactiviation.
  • This may result in a falsely low CPK level.
  • False-Positive Tests for Ascorbic Acid Mesna may cause false-positive reactions in Tillman’s reagent-based urine screening tests for ascorbic acid.
  • 5.5 Use in Patients with a History of Adverse Reactions to Thiol Compounds Mesna is a thiol compound, i.e., a sulfhydryl (SH) group-containing organic compound.
  • Hypersensitivity reactions to mesna and to amifostine, another thiol compound, have been reported.
  • It is not clear whether patients who experienced an adverse reaction to a thiol compound are at increased risk for a hypersensitivity reaction to mesna.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

  • Risk Summary Mesna injection is used in combination with ifosfamide or other cytotoxic agents.
  • Ifosfamide can cause fetal harm when administered to a pregnant woman.
  • Refer to the ifosfamide prescribing information for more information on use during pregnancy.
  • Mesna injection contains the preservative benzyl alcohol.
  • Because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4) ] .
  • The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown.
  • All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
  • In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
  • Data Animal Data Mesna injection is used in combination with ifosfamide or other cytotoxic agents.
  • Ifosfamide can cause fetal harm including embryo-fetal lethality.
  • Refer to the ifosfamide prescribing information for more information on use during pregnancy.
  • In embryo-fetal development studies, oral administration of mesna to pregnant rats (500, 1,000, 1,500, and 2,000 mg/kg) and rabbits (500 and 1,000 mg/kg) during the period of organogenesis revealed no adverse developmental outcomes at doses approximately 10 times the maximum recommended total daily human equivalent dose based on body surface area.
  • 8.3 Females and Males of Reproductive Potential Mesna injection is used in combination with ifosfamide or other cytotoxic agents.
  • Ifosfamide can cause fetal harm when administered to a pregnant woman.
  • Refer to the ifosfamide prescribing information for more information on contraception and effects on fertility.
  • Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiation of mesna injection in combination with ifosfamide.
  • Contraception Females Advise females of reproductive potential to use effective contraception during treatment with mesna injection in combination with ifosfamide and for 6 months after the last dose.
  • Males Advise males with female partners of reproductive potential to use effective contraception during treatment with mesna injection in combination with ifosfamide and for 3 months after the last dose.
  • 8. USE IN SPECIFIC POPULATIONS
  • Pregnancy:
  • Mesna injection in combination with ifosfamide can cause fetal harm. Advise patients of potential risk to a fetus. ( 8.1 )
  • Lactation: Do not breastfeed. ( 8.2 )
  • Females and Males of Reproductive Potential:
  • Advise patients to use effective contraception. Verify pregnancy status prior to initiation of mesna injection in combination with ifosfamide. ( 8.3 )
  • Pediatric use:
  • In premature neonates and low-birth weight infants,
  • avoid use of benzyl alcohol–containing solutions. ( 8.4 )
  • Geriatric use:
  • Dose selection should be cautious. ( 8.5 ) 8.1 Pregnancy Risk Summary Mesna injection is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide can cause fetal harm when administered to a pregnant woman. Refer to the ifosfamide prescribing information for more information on use during pregnancy. Mesna injection contains the preservative benzyl alcohol. Because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4) ] . The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Mesna injection is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide can cause fetal harm including embryo-fetal lethality. Refer to the ifosfamide prescribing information for more information on use during pregnancy. In embryo-fetal development studies, oral administration of mesna to pregnant rats (500, 1,000, 1,500, and 2,000 mg/kg) and rabbits (500 and 1,000 mg/kg) during the period of organogenesis revealed no adverse developmental outcomes at doses approximately 10 times the maximum recommended total daily human equivalent dose based on body surface area. 8.2 Lactation Risk Summary Mesna injection is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide is excreted in breast milk. Refer to the ifosfamide prescribing information for more information on use during lactation. There are no data on the presence of mesna in human or animal milk, the effect on the breastfed child, or the effect on milk production. Mesna injection contains the preservative benzyl alcohol. Because benzyl alcohol is rapidly metabolized by a lactating woman, benzyl alcohol exposure in the breastfed infant is unlikely. However, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4) ]. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment and for 1 week after the last dose of mesna or ifosfamide. 8.3 Females and Males of Reproductive Potential Mesna injection is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide can cause fetal harm when administered to a pregnant woman. Refer to the ifosfamide prescribing information for more information on contraception and effects on fertility. Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiation of mesna injection in combination with ifosfamide. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with mesna injection in combination with ifosfamide and for 6 months after the last dose. Males Advise males with female partners of reproductive potential to use effective contraception during treatment with mesna injection in combination with ifosfamide and for 3 months after the last dose. 8.4 Pediatric Use Mesna injection contains the preservative benzyl alcohol which has been associated with serious adverse reactions and death when administered intravenously to premature neonates and low birth weight infants.
  • Avoid use of mesna injection in premature neonates and low-birth weight infants [see Warnings and Precautions (5.3) ] . 8.5 Geriatric Use Clinical studies of mesna injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The ratio of ifosfamide to mesna should remain unchanged. 8.6 Use in Patients with Renal Impairment No clinical studies were conducted to evaluate the effect of renal impairment on the pharmacokinetics of mesna injection. 8.7 Use in Patients with Hepatic Impairment No clinical studies were conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of mesna injection.

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

No clinical drug interaction studies have been conducted with mesna.

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

  • 10.
  • OVERDOSAGE There is no known antidote for mesna injection.
  • In a clinical trial, 11 patients received intravenous mesna injection 10 mg/kg to 66 mg/kg per day for 3 to 5 days.
  • Patients also received ifosfamide or cyclophosphamide.
  • Adverse reactions included nausea, vomiting, diarrhea and fever.
  • An increased rate of these adverse reactions has also been found in oxazaphosphorine-treated patients receiving ≥80 mg mesna injection per kg per day intravenously compared with patients receiving lower doses or hydration treatment only.
  • Postmarketing, administration of 4.5 g to 6.9 g of mesna resulted in hypersensitivity reactions including mild hypotension, shortness of breath, asthma exacerbation, rash, and flushing.

Quoted from the official label, section “Overdosage”.

Use in children

  • Mesna injection contains the preservative benzyl alcohol which has been associated with serious adverse reactions and death when administered intravenously to premature neonates and low birth weight infants.
  • Avoid use of mesna injection in premature neonates and low-birth weight infants [see Warnings and Precautions (5.3) ] .

Quoted from the official label, section “Pediatric Use”.

Use in older people

  • Clinical studies of mesna injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
  • In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
  • The ratio of ifosfamide to mesna should remain unchanged.

Quoted from the official label, section “Geriatric Use”.

Side effects

  • 6.
  • ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling.
  • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Dermatological Toxicity [see Warnings and Precautions (5.2) ] Benzyl Alcohol Toxicity [see Warnings and Precautions (5.3) ] Laboratory Test Interferences [see Warnings and Precautions (5.4) ] Use in Patients with a History of Adverse Reactions to Thiol Compounds [see Warnings and Precautions (5.5) ] The most common adverse reactions (> 10%) when mesna injection is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.
  • ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eugia US LLC at 1-866-850-2876, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
  • Mesna injection adverse reaction data are available from four Phase 1 studies in which single intravenous doses of 600 to 1,200 mg mesna injection without concurrent chemotherapy were administered to a total of 53 healthy volunteers and single oral doses of 600 to 2,400 mg of MESNEX tablets were administered to a total of 82 healthy volunteers.
  • The most frequently reported side effects (observed in two or more healthy volunteers) for healthy volunteers receiving single doses of mesna injection alone were headache, injection site reactions, flushing, dizziness, nausea, vomiting, somnolence, diarrhea, anorexia, fever, pharyngitis, hyperesthesia, influenza-like symptoms, and coughing.
  • In two Phase 1 multiple-dose studies where healthy volunteers received MESNEX tablets alone or intravenous mesna followed by repeated doses of MESNEX tablets, flatulence and rhinitis were reported.
  • In addition, constipation was reported by healthy volunteers who had received repeated doses of intravenous mesna injection.
  • Additional adverse reactions in healthy volunteers receiving mesna injection alone included injection site reactions, abdominal pain/colic, epigastric pain/burning, mucosal irritation, lightheadedness, back pain, arthralgia, myalgia, conjunctivitis, nasal congestion, rigors, paresthesia, photophobia, fatigue, lymphadenopathy, extremity pain, malaise, chest pain, dysuria, pleuritic pain, dry mouth, dyspnea, and hyperhidrosis.
  • In healthy volunteers, mesna was commonly associated with a rapid (within 24 hours) decrease in lymphocyte count, which was generally reversible within one week of administration.
  • Because mesna is used in combination with ifosfamide or ifosfamide-containing chemotherapy regimens, it is difficult to distinguish the adverse reactions which may be due to mesna from those caused by the concomitantly administered cytotoxic agents.
  • Adverse reactions reasonably associated with mesna administered intravenously and orally in four controlled studies in which patients received ifosfamide or ifosfamide-containing regimens are presented in Table 3 .
  • Table 3:
  • Adverse Reactions in ≥5% of Patients Receiving Mesna in combination with Ifosfamide-containing Regimens Mesna Regimen Intravenous-Intravenous-Intravenous 1 Intravenous-Oral-Oral 1 1 Intravenous dosing of ifosfamide and mesna followed by either intravenous or oral doses of mesna according to the applicable dosage schedule [see Dosage and Administration (2) ].
  • N exposed 119 (100.0%) 119 (100%) Incidence of AEs 101 (84.9%) 106 (89.1%) Nausea 65 (54.6) 64 (53.8) Vomiting 35 (29.4) 45 (37.8) Constipation 28 (23.5) 21 (17.6) Leukopenia 25 (21.0) 21 (17.6) Fatigue 24 (20.2) 24 (20.2) Fever 24 (20.2) 18 (15.1) Anorexia 21 (17.6) 19 (16.0) Thrombocytopenia 21 (17.6) 16 (13.4) Anemia 20 (16.8) 21 (17.6) Granulocytopenia 16 (13.4) 15 (12.6) Asthenia 15 (12.6) 21 (17.6) Abdominal Pain 14 (11.8) 18 (15.1) Alopecia 12 (10.1) 13 (10.9) Dyspnea 11 (9.2) 11 (9.2) Chest Pain 10 (8.4) 11 (9.2) Hypokalemia 10 (8.4) 11 (9.2) Diarrhea 9 (7.6) 17 (14.3) Dizziness 9 (7.6) 5 (4.2) Headache 9 (7.6) 13 (10.9) Pain 9 (7.6) 10 (8.4) Sweating Increased 9 (7.6) 2 (1.7) Back Pain 8 (6.7) 6 (5.0) Hematuria 8 (6.7) 7 (5.9) Injection Site Reaction 8 (6.7) 10 (8.4) Edema 8 (6.7) 9 (7.6) Edema Peripheral 8 (6.7) 8 (6.7) Somnolence 8 (6.7) 12 (10.1) Anxiety 7 (5.9) 4 (3.4) Confusion 7 (5.9) 6 (5.0) Face Edema 6 (5.0) 5 (4.2) Insomnia 6 (5.0) 11 (9.2) Coughing 5 (4.2) 10 (8.4) Dyspepsia 4 (3.4) 6 (5.0) Hypotension 4 (3.4) 6 (5.0) Pallor 4 (3.4) 6 (5.0) Dehydration 3 (2.5) 7 (5.9) Pneumonia 2 (1.7) 8 (6.7) Tachycardia 1 (0.8) 7 (5.9) Flushing 1 (0.8) 6 (5.0)
  • 6.2 Postmarketing Experience The following adverse reactions have been reported in the postmarketing experience of patients receiving mesna injection in combination with ifosfamide or similar drugs, making it difficult to distinguish the adverse reactions which may be due to mesna injection from those caused by the concomitantly administered cytotoxic agents.
  • Because these reactions are reported from a population of unknown size, precise estimates of frequency cannot be made.
  • Cardiovascular :
  • Hypertension Gastrointestinal :
  • Dysgeusia Hepatobiliary :
  • Hepatitis Nervous System :
  • Convulsion Respiratory :
  • Hemoptysis

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

  • 17.
  • PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information).
  • Hypersensitivity Advise the patient to discontinue mesna injection and seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction, including systemic anaphylactic reactions occur [see Warnings and Precautions (5.1) ].
  • Dosing Instructions Advise the patient to take mesna injection at the exact time and in the exact amount as prescribed.
  • Advise the patient to contact their healthcare provider if they vomit within 2 hours of taking oral MESNEX, or if they miss a dose of oral MESNEX [see Dosage and Administration (2.2) ].
  • Hemorrhagic Cystitis Mesna injection does not prevent hemorrhagic cystitis in all patients nor does it prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide.
  • Advise the patient to report to their healthcare provider if his/her urine has turned a pink or red color [see Dosage and Administration (2.3) ].
  • Advise the patient to drink 1 to 2 liters of fluid each day during mesna injection therapy [see Dosage and Administration (2.3) ].
  • Dermatologic Toxicity Advise the patient that Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms and bullous and ulcerative skin and mucosal reactions have occurred with mesna injection.
  • Advise the patient to report to their healthcare provider if signs and symptoms of these syndromes occur [see Warnings and Precautions (5.2) ] .
  • Benzyl Alcohol Toxicity Advise patients that serious adverse reactions are associated with the benzyl alcohol found in mesna injection and other medications in premature neonates and low-birth weight infants [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4) ] .
  • Embryo-Fetal Toxicity Mesna injection is used in combination with ifosfamide.
  • Ifosfamide or other cytotoxic agents can cause fetal harm when administered to a pregnant woman.
  • Inform female patients of the risk to a fetus and potential loss of the pregnancy.
  • Advise females to inform their healthcare provider if they are pregnant or become pregnant [see Use in Specific Populations (8.1) ] .
  • Contraception Advise females of reproductive potential to use effective contraception during treatment with mesna injection in combination with ifosamide and for 6 months after the last dose [see Use in Specific Populations (8.3) ] .
  • Advise male patients with female partners of reproductive potential to use effective contraception during treatment with mesna injection in combination with ifosamide and for 3 months after the last dose [see Use in Specific Populations (8.3) ] .
  • Lactation Advise lactating women not to breastfeed during treatment with mesna injection or ifosfamide and for 1 week after the last dose [see Use in Specific Populations (8.2) ].
  • All brands listed are the trademarks of their respective owners and are not trademarks of Eugia Pharma Specialities Limited.
  • Distributed by: Eugia US LLC 279 Princeton-Hightstown Rd.
  • E.
  • Windsor, NJ 08520 Manufactured by:
  • Eugia Pharma Specialities Limited Hyderabad – 500032 India

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

  • 3. DOSAGE FORMS AND STRENGTHS Mesna injection:
  • 1 g/10 mL Multiple-Dose Vial, 100 mg/mL Injection:
  • 1g (100 mg/mL) Multidose vials ( 3 )

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

  • 16.
  • HOW SUPPLIED/STORAGE AND HANDLING Mesna injection, 1 g/10 mL (100 mg/mL) is a clear, colorless solution available as:
  • NDC CONCENTRATION PACKAGE FACTOR 55150-520-01 1 g/10 mL Multi-Dose Vial 1 Vial per Carton
  • Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] If mesna injection is co-administered with ifosfamide, refer to the ifosfamide prescribing information for safe handling instructions.
  • The vial stopper is not made with natural rubber latex.

Quoted from the official label, section “How Supplied”.

What is in it

  • 11.
  • DESCRIPTION Mesna injection is a detoxifying agent to inhibit the hemorrhagic cystitis induced by ifosfamide.
  • The active ingredient, mesna, USP is a synthetic sulfhydryl compound designated as sodium-2- sulphanylethanesulphonate with a molecular formula of C 2 H 5 NaO 3 S 2 and a molecular weight of 164.2.
  • Its structural formula is as follows:
  • HS–CH 2 –CH 2 SO 3 –Na + Mesna injection is a sterile, nonpyrogenic, aqueous solution of clear and colorless appearance in clear glass multiple-dose vials for intravenous administration.
  • Mesna injection contains 100 mg/mL mesna, USP, 0.25 mg/mL edetate disodium and sodium hydroxide for pH adjustment.
  • Mesna injection multiple-dose vials also contain 10.4 mg/mL of benzyl alcohol as a preservative.
  • The solution has a pH range between 7.5 and 8.5.

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (7)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 7 of 7

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Spain3 matching products

Every strength and form (5)

France1 matching products

Every strength and form (6)

CanadaNo exact match for this strength and form

Every strength and form (3)

Netherlands3 matching products

Every strength and form (5)

Details

Made byEugia US LLC
Active substanceMesna
Strength100 mg/mL
FormInjection, Solution
RouteIntravenous
Packs1 VIAL, MULTI-DOSE in 1 BOX / 10 mL in 1 VIAL, MULTI-DOSE
NDC55150-520

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

7 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Mesna100 mg/mLPrescription onlyInjection, Solution Hikma Pharmaceuticals USA Inc. · MesnaMesna100 mg/mLPrescription onlyInjection, Solution Baxter Healthcare Company · MesnaMesna100 mg/mLPrescription onlyInjection, Solution Sagent Pharmaceuticals · MesnaMesna400 mgPrescription onlyTablet, Film Coated Ingenus Pharmaceuticals, LLC · MesnaMesna100 mg/mLPrescription onlyInjection, Solution Fresenius Kabi USA, LLC · MesnaMesnex100 mg/mLPrescription onlyInjection, Solution Baxter Healthcare Company · Mesna

See every product with Mesna